MIR194-2HG

Summary

MIR194-2HG (MIR194-2 host gene, HGNC:51946) is a long non-coding RNA gene on chromosome 11q13.1.

Predicted to be involved in miRNA-mediated post-transcriptional gene silencing. Predicted to be part of RISC complex.

Source: NCBI Gene 105369343 — RefSeq curated summary.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:51946
Approved symbol	MIR194-2HG
Name	MIR194-2 host gene
Location	11q13.1
Locus type	RNA, long non-coding
Status	Approved
Ensembl gene	ENSG00000229719
Ensembl biotype	lncRNA
Entrez	105369343
RNAcentral	URS00008E3A09 — lncRNA, 2521 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 6 lncRNA

ENST00000413053, ENST00000687544, ENST00000710929, ENST00000710930, ENST00000719982, ENST00000719983

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000413053 — 2 exons

Exon	Start	End
ENSE00001608574	64893411	64893449
ENSE00004014122	64889560	64893167

Expression profiles

Bgee: expression breadth broad, 79 present calls, max score 90.26.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.7668 / max 209.0251, expressed in 59 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
120508	0.7668	59

Top tissues by expression

183 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mucosa of transverse colon	UBERON:0004991	90.26	gold quality
transverse colon	UBERON:0001157	83.34	gold quality
small intestine Peyer’s patch	UBERON:0003454	80.51	gold quality
rectum	UBERON:0001052	78.85	gold quality
small intestine	UBERON:0002108	78.34	gold quality
colonic epithelium	UBERON:0000397	75.45	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	72.88	silver quality
intestine	UBERON:0000160	70.55	gold quality
colon	UBERON:0001155	68.37	gold quality
bone marrow cell	CL:0002092	68.21	silver quality
body of stomach	UBERON:0001161	67.49	gold quality
large intestine	UBERON:0000059	67.34	gold quality
right lobe of liver	UBERON:0001114	67.15	gold quality
gingival epithelium	UBERON:0001949	66.88	gold quality
superficial temporal artery	UBERON:0001614	65.92	gold quality
stomach	UBERON:0000945	64.55	gold quality
mucosa of stomach	UBERON:0001199	63.90	gold quality
duodenum	UBERON:0002114	62.70	gold quality
vermiform appendix	UBERON:0001154	61.95	gold quality
mucosa of paranasal sinus	UBERON:0005030	61.19	gold quality
gall bladder	UBERON:0002110	60.55	gold quality
gingiva	UBERON:0001828	59.66	gold quality
hindlimb stylopod muscle	UBERON:0004252	59.16	gold quality
germinal epithelium of ovary	UBERON:0001304	59.04	gold quality
body of pancreas	UBERON:0001150	58.17	gold quality
liver	UBERON:0002107	57.48	gold quality
caecum	UBERON:0001153	57.20	gold quality
pancreas	UBERON:0001264	55.85	gold quality
tonsil	UBERON:0002372	55.65	gold quality
muscle layer of sigmoid colon	UBERON:0035805	55.34	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	12.57

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 5)

• miR-194 regulated the progression of hepatocellular carcinoma through directly inhibiting the expression of MAP4K4 (PMID:26722431)
• These findings suggested that miR-194 inhibits proliferation and metastasis and reverses cisplatin-resistance of non-small cell lung cancer cells (PMID:26909612)
• The present study…identified miR-194 as predictive biomarker of response to preoperative chemoradiotherapy for locally advanced rectal cancer (PMID:28870889)
• Downregulation of serum miR-194 predicts poor prognosis in osteosarcoma patients. (PMID:32172218)
• miR-194-5p inhibits SLC40A1 expression to induce cisplatin resistance in ovarian cancer. (PMID:32534701)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.